EMA Authorised: Kentera (previously Oxybutynin Nicobrand) (oxybutynin) — Teva B.V.

View source ↗

Summary

The European Medicines Agency authorised Kentera, a transdermal oxybutynin patch by Teva B.V., for urinary incontinence associated with urge. This marks the EU …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder
• Urinary Incontinence

Drugs mentioned

• Kentera (oxybutynin)

Snippet

Status: Authorised. Therapeutic area: Urinary Incontinence, Urge. MAH: Teva B.V.. Decision date: 07/04/2025